PAREXEL expands presence in Japan with new office in Nagoya

PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, today announced that the Company has opened a new office in Nagoya, Japan to support a growing demand for a broad range of clinical development and regulatory consulting capabilities in the country and throughout the Asia/Pacific region. This office further expands PAREXEL's presence in Japan, which includes locations in Tokyo and Kobe. PAREXEL now has 18 offices throughout important biopharmaceutical centers in the Asia/Pacific region, which in addition to Japan also includes a strong presence in Australia, China, India, Indonesia, Malaysia, the Philippines, Singapore, South Korea, Taiwan, and Thailand.

"Japan continues to maintain its position as the second largest pharmaceutical market globally, and is among the most mature markets within the Asia/Pacific region. Japan is attractive to our worldwide client base for inclusion in global studies not only for its market potential but also for its high quality data, advanced technologies, and large pool of well-trained professionals. Clients have continued to rely on PAREXEL's in-depth expertise in Japan as well as our fully-integrated, harmonized global processes and standards to support their programs," said Josef von Rickenbach, Chairman and Chief Executive Officer, PAREXEL International.

"The opening of our office in Nagoya builds on our established presence and long-term, ongoing commitment to Japan. PAREXEL's expansion in Japan allows us to further assist locally-based clients with regional and global market access opportunities. Our regulatory and clinical experts are supporting what we call 'Japan plus Asia' studies since recent regulatory changes allow for inclusion of non-Japanese data for registration purposes. We are also supporting Japan-based biopharmaceutical companies with simultaneous global clinical studies across a broad range of therapeutic areas, and providing eClinical solutions to accelerate the clinical development process," said Mr. von Rickenbach.

When PAREXEL was founded 28 years ago, the Company began helping clients based in Japan with U.S. regulatory filings. In 1995, PAREXEL opened its first office in Japan in Kobe. Since then, PAREXEL has continued to expand its work with Japanese companies to assist them with the development and commercialization of their products.

The opening of PAREXEL's latest office in the Asia/Pacific region, where the Company has had a presence for approximately 15 years, reinforces its long-term commitment to providing clients with a high level of service and quality clinical development solutions in this geography. Today, PAREXEL is one of the area's leading providers of biopharmaceutical services, helping clients design drug development programs and conduct studies regionally and internationally. PAREXEL experts support biopharmaceutical companies in accessing diverse patient populations, navigating regulatory issues, identifying investigators, and ensuring data quality throughout the Asia/Pacific region.